Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ajay Kumar Jain is active.

Publication


Featured researches published by Ajay Kumar Jain.


American Journal of Physiology-gastrointestinal and Liver Physiology | 2012

Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs

Ajay Kumar Jain; Barbara J. Stoll; Douglas G. Burrin; Jens J. Holst; David D. Moore

Total parenteral nutrition (TPN) is essential for patients with impaired gut function but leads to parenteral nutrition-associated liver disease (PNALD). TPN disrupts the normal enterohepatic circulation of bile acids, and we hypothesized that it would decrease intestinal expression of the newly described metabolic hormone fibroblast growth factor-19 (FGF19) and also glucagon-like peptides-1 and -2 (GLP-1 and GLP-2). We tested the effects of restoring bile acids by treating a neonatal piglet PNALD model with chenodeoxycholic acid (CDCA). Neonatal pigs received enteral feeding (EN), TPN, or TPN + CDCA for 14 days, and responses were assessed by serum markers, histology, and levels of key regulatory peptides. Cholestasis and steatosis were demonstrated in the TPN group relative to EN controls by elevated levels of serum total and direct bilirubin and also bile acids and liver triglyceride (TG) content. CDCA treatment improved direct bilirubin levels by almost fourfold compared with the TPN group and also normalized serum bile acids and liver TG. FGF19, GLP-1, and GLP-2 were decreased in plasma of the TPN group compared with the EN group but were all induced by CDCA treatment. Intestinal mucosal growth marked by weight and villus/crypt ratio was significantly reduced in the TPN group compared with the EN group, and CDCA treatment increased both parameters. These results suggest that decreased circulating FGF19 during TPN may contribute to PNALD. Moreover, we show that enteral CDCA not only resolves PNALD but acts as a potent intestinal trophic agent and secretagogue for GLP-2.


Clinical Gastroenterology and Hepatology | 2014

Relationship Between Changes in Serum Levels of Keratin 18 and Changes in Liver Histology in Children and Adults With Nonalcoholic Fatty Liver Disease

Raj Vuppalanchi; Ajay Kumar Jain; Ross Deppe; Katherine P. Yates; Megan Comerford; Howard C. Masuoka; Brent A. Neuschwander-Tetri; Rohit Loomba; Elizabeth M. Brunt; David E. Kleiner; Jean P. Molleston; Jeffrey B. Schwimmer; Joel E. Lavine; James Tonascia; Naga Chalasani

BACKGROUND & AIMS Cross-sectional studies have associated serum levels of the keratin 18 (K18) fragment with histologic features of liver in individuals with nonalcoholic fatty liver disease (NAFLD). We investigated the relationship between changes in serum levels of K18 and changes in liver histology in adults and children with NAFLD. METHODS We measured levels of K18 in stored serum samples collected at baseline and various time points from 231 adults with nonalcoholic steatohepatitis and 152 children with NAFLD who participated in 2 separate prospective randomized clinical trials. Liver biopsy specimens collected at baseline and week 96 were reviewed centrally. RESULTS There were greater decreases in serum levels of K18 in adults with histologic improvement at week 96 than in those without histologic improvement at week 16 (decrease, 193 ± 293 vs 139 ± 467 U/L; P < .001), week 48 (decrease, 232 ± 360 vs 113 ± 425 U/L; P < .001), or week 96 (decrease, 269 ± 368 vs 97 ± 400 U/L; P < .001). There were greater decreases in serum levels of K18 in children with histologic improvements than in those without histologic improvements at week 48 (decrease, 197 ± 467 vs 47 ± 350 U/L; P = .005) and week 96 (decrease, 206 ± 432 vs 2 ± 474 U/L; P < .001). However, reductions in serum levels of K18 were not better than reductions in levels of alanine aminotransferase in identifying adults with histologic improvement (area under the receiver operator characteristic [AUROC], 0.71; 95% confidence interval [CI], 0.63-0.80; vs AUROC, 0.68; 95% CI, 0.61-0.79; P = .34) or children (AUROC, 0.72; 95% CI, 0.63-0.81; vs AUROC, 0.79; 95% CI, 0.70-0.87; P = .42). CONCLUSIONS Decreases in serum levels of K18 are associated strongly with improved liver histologies in adults or children with NAFLD. However, reductions in K18 do not perform better than those in alanine aminotransferase level in identifying histologic changes in NAFLD.


Journal of Clinical Investigation | 2015

Elevated copper impairs hepatic nuclear receptor function in Wilson’s disease

Clavia Ruth Wooton-Kee; Ajay Kumar Jain; Martin Wagner; Michael A. Grusak; Milton J. Finegold; Svetlana Lutsenko; David D. Moore

Wilsons disease (WD) is an autosomal recessive disorder that results in accumulation of copper in the liver as a consequence of mutations in the gene encoding the copper-transporting P-type ATPase (ATP7B). WD is a chronic liver disorder, and individuals with the disease present with a variety of complications, including steatosis, cholestasis, cirrhosis, and liver failure. Similar to patients with WD, Atp7b⁻/⁻ mice have markedly elevated levels of hepatic copper and liver pathology. Previous studies have demonstrated that replacement of zinc in the DNA-binding domain of the estrogen receptor (ER) with copper disrupts specific binding to DNA response elements. Here, we found decreased binding of the nuclear receptors FXR, RXR, HNF4α, and LRH-1 to promoter response elements and decreased mRNA expression of nuclear receptor target genes in Atp7b⁻/⁻ mice, as well as in adult and pediatric WD patients. Excessive hepatic copper has been described in progressive familial cholestasis (PFIC), and we found that similar to individuals with WD, patients with PFIC2 or PFIC3 who have clinically elevated hepatic copper levels exhibit impaired nuclear receptor activity. Together, these data demonstrate that copper-mediated nuclear receptor dysfunction disrupts liver function in WD and potentially in other disorders associated with increased hepatic copper levels.


Journal of Pediatric Gastroenterology and Nutrition | 2013

Estimation of fish and ω-3 fatty acid intake in pediatric nonalcoholic fatty liver disease.

David E. St-Jules; Corilee A. Watters; Elizabeth M. Brunt; Lynne R. Wilkens; Rachel Novotny; Patricia Belt; Joel E. Lavine; Stephanie H. Abrams; Ryan Himes; Rajesh Krisnamurthy; Leanel Maldonado; Beverly Morris; Kimberlee Bernstein; Kim M. Cecil; Stephanie DeVore; Rohit Kohli; Kathleen Lake; Daniel J. Podberesky; Crystal Slaughter; Stavra A. Xanthakos; Gerald Behr; Ali Mencin; Nadia Ovchinsky; Elena Reynoso; Adina Alazraki; Rebecca Cleeton; Saul J. Karpen; Nicholas Raviele; Miriam B. Vos; Elizabeth Byam

Aims: Fish and &ohgr;-3 fatty acids are reported to be beneficial in pediatric nonalcoholic fatty liver disease (NAFLD), but no studies have assessed their relation to histological severity. The objectives of this study were to evaluate the dietary intake of fish and &ohgr;-3 fatty acids in children with biopsy-proven NAFLD, and examine their association with serological and histological indicators of disease. Methods: This was a cross-sectional analysis of 223 children (6–18 years) who participated in the Treatment of Nonalcoholic Fatty Liver Disease in Children trial or the NAFLD Database study conducted by the Nonalcoholic Steatohepatitis Clinical Research Network. The distribution of fish and &ohgr;-3 fatty acid intake was determined from responses to the Block Brief 2000 Food Frequency Questionnaire, and analyzed for associations with serum alanine aminotransferase, histological features of fatty liver disease, and diagnosis of steatohepatitis after adjusting for demographic, anthropometric, and dietary variables. Results: The minority of subjects consumed the recommended 8 ounces of fish per week (22/223 [10%]) and 200 mg of long-chain &ohgr;-3 fatty acids per day (12/223 [5%]). Lack of fish and long-chain &ohgr;-3 fatty acid intake was associated with greater portal (P = 0.03 and P = 0.10, respectively) and lobular inflammation (P = 0.09 and P = 0.004, respectively) after controlling for potential confounders. Conclusions: Fish and &ohgr;-3 fatty acid intake was insufficient in children with NAFLD, which may increase susceptibility to hepatic inflammation. Patients with pediatric NAFLD should be encouraged to consume the recommended amount of fish per week.


Advances in Hepatology | 2014

Newly Identified Mechanisms of Total Parenteral Nutrition Related Liver Injury

Ajay Kumar Jain; Jeffrey H. Teckman

Total parenteral nutrition (TPN), a lifesaving therapy, involves providing nutrition by bypassing the gut. Unfortunately it is associated with significant complications including gut atrophy and parenteral nutrition associated liver disease (PNALD). PNALD includes steatosis, cholestasis, disrupted glucose metabolism, disrupted lipid metabolism, cirrhosis, and liver failure. The etiopathogenesis remains poorly defined; however, an altered enterohepatic circulation, disrupting nuclear receptor signaling, is emerging as a promising mechanism. Rodent models and our piglet TPN model have shown that, during regular feeding, bile acids activate farnesoid X receptor (FXR) in the gut and enhance fibroblast growth factor 19 (FGF19) level. FGF19 regulates bile acid, lipid, and glucose metabolism. We noted reduced FGF19 with TPN use and substantial improvement in FGF19, bilirubin, and metabolic profiles with the FXR agonist chenodeoxycholic acid (CDCA). Additionally, CDCA caused gut growth and enhanced expression of glucagon like peptides (GLPs). GLPs regulate gut trophic effects, insulin, glucose homeostasis, and hepatic steatosis. GLP secretion is regulated by the CDCA activated receptor TGR5. This leads to an important conclusion that, in addition to a disrupted FXR-FGF19 axis, a disrupted TGR5-GLP axis may contribute to TPN related pathologies. Thus modulators of FXR-FGF19 and the TGR5-GLP axis could help bring forward novel treatment strategies.


Journal of Parenteral and Enteral Nutrition | 2018

No Gut No Gain! Enteral Bile Acid Treatment Preserves Gut Growth but Not Parenteral Nutrition-Associated Liver Injury in a Novel Extensive Short Bowel Animal Model

Gustavo A. Villalona; Amber Price; Keith Blomenkamp; Chandrashekhara Manithody; Saurabh Saxena; Thomas L. Ratchford; Matthew Westrich; Vindhya Kakarla; Shruthika Pochampally; William Phillips; Nicole Heafner; Niraja Korremla; Jose Greenspon; Miguel Guzman; Ajay Kumar Jain

BACKGROUND Parenteral nutrition (PN) provides nutrition intravenously; however, this life-saving therapy is associated with significant liver disease. Recent evidence indicates improvement in PN-associated injury in animals with intact gut treated with enteral bile acid (BA), chenodeoxycholic acid (CDCA), and a gut farnesoid X receptor (FXR) agonist, which drives the gut-liver cross talk (GLCT). We hypothesized that similar improvement could be translated in animals with short bowel syndrome (SBS). METHODS Using piglets, we developed a novel 90% gut-resected SBS model. Fifteen SBS piglets receiving PN were given CDCA or control (vehicle control) for 2 weeks. Tissue and serum were analyzed posteuthanasia. RESULTS CDCA increased gut FXR (quantitative polymerase chain reaction; P = .008), but not downstream FXR targets. No difference in gut fibroblast growth factor 19 (FGF19; P = .28) or hepatic FXR (P = .75), FGF19 (P = .86), FGFR4 (P = .53), or Cholesterol 7 α-hydroxylase (P = .61) was noted. PN resulted in cholestasis; however, no improvement was noted with CDCA. Hepatic fibrosis or immunostaining for Ki67, CD3, or Cytokeratin 7 was not different with CDCA. PN resulted in gut atrophy. CDCA preserved (P = .04 vs control) gut mass and villous/crypt ratio. The median (interquartile range) for gut mass for control was 0.28 (0.17-0.34) and for CDCA was 0.33 (0.26-0.46). CONCLUSIONS We note that, unlike in animals with intact gut, in an SBS animal model there is inadequate CDCA-induced activation of gut-derived signaling to cause liver improvement. Thus, it appears that activation of GLCT is critically dependent on the presence of adequate gut. This is clinically relevant because it suggests that BA therapy may not be as effective for patients with SBS.


Journal of Pediatric Gastroenterology and Nutrition | 2010

Rectal ulcer with an elusive diagnosis: all that ulcers is not Crohn disease.

Ajay Kumar Jain; Kathleen J. Motil; Stuart L. Abramson; Yong S Han; Nina Tatevian

JPGN Volume 51, N er is an uncommon fin disease. Although infl A single rectal ulc ding in children with gastrointestinal ammatory bowel disease (IBD) is foremost among the differential diagnoses, a primary immunological defect should not be forgotten. Because of the paucity of literature on the association of rectal ulcers and immunodeficiency disorders, we describe a patient with primary leukocyte adhesion deficiency (LAD) who presented with a fever, rash, and a rectal ulcer.


Gastroenterology | 2014

Mo1679 Development and Validation of a Novel Ultra-Mobile Ambulatory Total Parenteral Nutrition Model

Ajay Kumar Jain; Keith Blomenkamp; Jonathan Rodrigues; Mike A. Carl; Victor Liou; Joy X. Wen; Frank Strebeck; Anna C. Knobeloch; Barbara J. Stoll; Douglas G. Burrin; John P. Long; Jeffrey Teckman

G A A b st ra ct s previously have described the presence of cytokines in saliva which also are present in blood and esophageal tissue and have been suggested as playing a fundamental role in the pathogenesis of EoE. However, the usefulness of these salivary cytokines in discriminating between patients with/without EoE and their potential correlation with esophageal eosinophilia have not been examined. Methods In this cross−sectional study, we collected saliva using oral swabs (OS; Salimetrics Oral Swab®, Salimetrics LLC, PA) at the time of upper gastrointestinal endoscopy in sixteen children being evaluated for gastroesophageal and/or dyspeptic symptoms. Children with oral lesions, neurodevelopmental disorders, inflammatory bowel disease, or celiac disease were excluded. Six children were diagnosed with EoE and ten children had no evidence of EoE and were considered Controls (Table). Esophageal histology was compared between groups. Salivary cytokines: IL−4, IL−5, and IL−13 were measured on a high sensitivity human multiplex platform, and eotaxin 3 (Eo3) and thymic stromal lymphopoietin (TSLP) by sandwich ELISA technique. Differences between groups were evaluated using the Wilcoxon rank sum test. Spearmans correlation was performed to examine potential associations between salivary cytokines and esophageal eosinophils per high powered field (eos/hpf). Results See Table. Age and sex were comparable between groups. Median salivary IL−5 and IL−4 concentrations were significantly greater in patients with EoE than in Controls. In contrast, there were no differences between groups in median IL−13, Eo3, or TSLP concentrations although values were numerically higher in patients with EoE. Salivary IL−4 and IL−5 were positively correlated with eos/hpf in the distal esophagus (Spearmans ρ=0.53; P=0.03 and ρ=0.56; P=0.02, respectively). In contrast, IL−13, Eo3, and TSLP did not correlate with histologic findings. Conclusions Our preliminary data suggest that salivary cytokines, specifically IL−4 and IL−5 have the potential to distinguish children with vs without EoE. Salivary concentrations of these cytokines appear to reflect esophageal eosinophilic infiltration in EoE. Confirmation of our findings in a larger sample with additional types of disease controls may simplify management and reduce the cost of caring for children with EoE. Table: Summary of results


Journal of Pediatric Gastroenterology and Nutrition | 2009

Colon cancer in a 16-year-old girl: Signet-ring cell carcinoma without microsatellite instability-an unusual suspect

Ajay Kumar Jain; Kathleen J. Motil; Oluyinka O. Olutoye; Sandy Cope-Yokoyama; Rachel A. Egler; Nina Tatevian

Received July 24, 2007 Address correspondenc MD, PhD, Children’s Nut ton, TX 77030 (e-mail: k This work is a public Agriculture/Agricultural Research Center, Departm cine, Houston, Texas. Thi funds from the Agricultur Agriculture under Coope The contents of this publi policies of the US Departm names, commercial produ the US government. The authors report no sion of Pediatric Surgery, Michael E. DeBakey Department of Surgery, §Section of Pedi epartment of Pediatrics, and jjDepartment of Pathology, Baylor College of Medicine, H Research Center, {Divi Oncology, D


Journal of Parenteral and Enteral Nutrition | 2018

Proceedings of the 2017 ASPEN Research Workshop—Gastric Bypass: Role of the Gut

Ajay Kumar Jain; Carel W. le Roux; Puneet Puri; Ali Tavakkoli; Nana Gletsu-Miller; Blandine Laferrère; Richard Kellermayer; John K. DiBaise; Robert G. Martindale; Bruce M. Wolfe

Collaboration


Dive into the Ajay Kumar Jain's collaboration.

Top Co-Authors

Avatar

David D. Moore

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Elizabeth M. Brunt

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Keith Blomenkamp

Cardinal Glennon Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Amber Price

Saint Louis University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Barbara J. Stoll

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

David E. Kleiner

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Douglas G. Burrin

Baylor College of Medicine

View shared research outputs
Researchain Logo
Decentralizing Knowledge